James Norris to Male
This is a "connection" page, showing publications James Norris has written about Male.
Connection Strength
0.225
-
Differential expression of epithelial and mesenchymal proteins in a panel of prostate cancer cell lines. J Urol. 2012 Aug; 188(2):632-8.
Score: 0.022
-
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
Score: 0.019
-
Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2008 Feb; 61(2):231-42.
Score: 0.016
-
Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36.
Score: 0.015
-
New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett. 2006 Aug 21; 580(19):4751-6.
Score: 0.015
-
Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
Score: 0.015
-
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
Score: 0.015
-
The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol. 2005 Feb; 1(1):115-23.
Score: 0.013
-
Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther. 2003 Apr; 10(4):330-9.
Score: 0.012
-
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72.
Score: 0.011
-
The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36.
Score: 0.010
-
Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer. Adv Cancer Res. 2018; 140:265-293.
Score: 0.008
-
Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer Res. 2017 12 15; 77(24):6950-6962.
Score: 0.008
-
Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochim Biophys Acta Mol Basis Dis. 2017 02; 1863(2):386-394.
Score: 0.008
-
Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling. PLoS One. 2013; 8(10):e76593.
Score: 0.006
-
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58.
Score: 0.006
-
Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis. J Cell Physiol. 2010 Mar; 222(3):546-55.
Score: 0.005
-
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
Score: 0.004
-
Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer. Connect Tissue Res. 2008; 49(3):265-9.
Score: 0.004
-
Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett. 2007 Oct 18; 256(1):101-11.
Score: 0.004
-
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
Score: 0.004
-
The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo. Immunology. 2004 Mar; 111(3):291-7.
Score: 0.003
-
A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity. Cancer Biol Ther. 2002 Mar-Apr; 1(2):163-7.
Score: 0.003